Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9081
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFrendy Setyawan, Muhamad-
dc.contributor.authorMertaniasih, Ni Made-
dc.contributor.authorSoedarsono, Soedarsono-
dc.date.accessioned2024-12-16T02:25:01Z-
dc.date.available2024-12-16T02:25:01Z-
dc.date.issued2023-10-01-
dc.identifier.issn2338-2732-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9081-
dc.description.abstractABSTRACT Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in the last 7 years with the treatment outcomes of pulmonary MDR-TB patients at a tertiary referral hospital in East Java. Methods: This study was a retrospective, descriptive, and data analysis on 1053 pulmonary MDR-TB patients in tertiary referral hospital Dr Soetomo, East Java, Indonesia, with the SPSS software version 25 and Microsoft Excel 2021. Results: The study analyzed the MDR-TB treatment regimen following the latest guidelines from WHO (2020) at a tertiary referral hospital in East Java. This study shows that a bedaquiline-containing regimen started in January 2015 to July 2022 with the percentage of distribution (1, 3, 11, 4, 18, 13, 29, 21)% consecutively in the regimen. The treatment outcome profile of MDR-TB patients shows the average percentage of cured (15%), died (12%), lost-to-follow-up cases (27%), moved to an individualized regimen or a different health facility (42%), and currently in the evaluation stage (4%). Overall from January 2017 to July 2022, the number of LTFU cases decreased (42, 46, 29, 19, 8, 4)%. However, the cured case fluctuated between 2017-2022 (16, 28, 26, 32)% respectively after Bdq started to be included in the regimen regularly for treating RR/MDR-TB. Conclusion: After seven years of study, we revealed an association between adding bedaquiline to the regimen and the treatment success and decreasing lost-to-follow-up cases. Keywords: MDR-TB treatment regimen, bedaquiline, pulmonary TB, treatment outcomesen_US
dc.language.isoenen_US
dc.publisherPerhimpunan Dokter Spesialis Penyakit dalam Indonesiaen_US
dc.subjectMDR-TB treatment regimen,en_US
dc.subjectbedaquiline,en_US
dc.subjectpulmonary TB,en_US
dc.subjecttreatment outcomesen_US
dc.titleThe Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquilineen_US
dc.typeArticleen_US
Appears in Collections:VOL 55 NO 4 2023

Files in This Item:
File Description SizeFormat 
430-439.pdf507.85 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.